Warning: The NCBI web site requires JavaScript to function. more...
Eph receptors in breast cancer: roles in tumor promotion and tumor suppression.
Vaught D, Brantley-Sieders DM, Chen J.
Breast Cancer Res. 2008;10(6):217. Epub 2008 Dec 22. Review.
Related citations
Eph receptor tyrosine kinases in tumor and tumor microenvironment.
Brantley-Sieders D, Schmidt S, Parker M, Chen J.
Curr Pharm Des. 2004;10(27):3431-42. Review.
EPH receptors in cancer.
Castaño J, Davalos V, Schwartz S Jr, Arango D.
Histol Histopathol. 2008 Aug;23(8):1011-23. Review.
Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application.
Fox BP, Kandpal RP.
Biochem Biophys Res Commun. 2004 Jun 11;318(4):882-92.
A paradigm shift in EPH receptor interaction: biological relevance of EPHB6 interaction with EPHA2 and EPHB2 in breast carcinoma cell lines.
Cancer Genomics Proteomics. 2011 Jul-Aug;8(4):185-93.
EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics.
Ireton RC, Chen J.
Curr Cancer Drug Targets. 2005 May;5(3):149-57. Review.
Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression.
Héroult M, Schaffner F, Augustin HG.
Exp Cell Res. 2006 Mar 10;312(5):642-50. Epub 2005 Dec 5. Review.
Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression.
Brantley-Sieders DM, Fang WB, Hicks DJ, Zhuang G, Shyr Y, Chen J.
FASEB J. 2005 Nov;19(13):1884-6. Epub 2005 Sep 15.
Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer.
Bierie B, Moses HL.
Nat Rev Cancer. 2006 Jul;6(7):506-20. Review.
R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.
Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W, Duan M, Torneros A, Yu J, Heckrodt TJ, Zhang J, Ding P, Apatira A, Chua J, Brandt R, Pine P, Goff D, Singh R, Payan DG, Hitoshi Y.
Cancer Res. 2010 Feb 15;70(4):1544-54. Epub 2010 Feb 9.
Crosstalk between integrin and receptor tyrosine kinase signaling in breast carcinoma progression.
Soung YH, Clifford JL, Chung J.
BMB Rep. 2010 May;43(5):311-8. Review.
Eph receptors and ephrins.
Himanen JP, Nikolov DB.
Int J Biochem Cell Biol. 2003 Feb;35(2):130-4. Review.
Ephrins and Eph receptors in stem cells and cancer.
Genander M, Frisén J.
Curr Opin Cell Biol. 2010 Oct;22(5):611-6. Review.
The ephrins and Eph receptors in angiogenesis.
Cheng N, Brantley DM, Chen J.
Cytokine Growth Factor Rev. 2002 Feb;13(1):75-85. Review.
The role of ephrins and Eph receptors in cancer.
Surawska H, Ma PC, Salgia R.
Cytokine Growth Factor Rev. 2004 Dec;15(6):419-33. Review.
'Eph'ective signaling: forward, reverse and crosstalk.
Murai KK, Pasquale EB.
J Cell Sci. 2003 Jul 15;116(Pt 14):2823-32. Review.
Eph-modulated cell morphology, adhesion and motility in carcinogenesis.
Wimmer-Kleikamp SH, Lackmann M.
IUBMB Life. 2005 Jun;57(6):421-31. Review.
The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling.
Brantley-Sieders DM, Zhuang G, Hicks D, Fang WB, Hwang Y, Cates JM, Coffman K, Jackson D, Bruckheimer E, Muraoka-Cook RS, Chen J.
J Clin Invest. 2008 Jan;118(1):64-78.
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.
Arpino G, Wiechmann L, Osborne CK, Schiff R.
Endocr Rev. 2008 Apr;29(2):217-33. Epub 2008 Jan 23. Review.
Regulation of angiogenesis by Eph-ephrin interactions.
Kuijper S, Turner CJ, Adams RH.
Trends Cardiovasc Med. 2007 Jul;17(5):145-51. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on